Deals
CSL is advancing clazakizumab for the treatment of cardiovascular events in end-stage kidney disease and will retain rights over the asset in this indication. Lilly will explore other conditions.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Lundbeck announced the acquisition aimed at eptinezumab, Alder’s investigational monoclonal antibody (mAb) for migraine prevention targeting the calcitonin gene-related peptide that has been submitted to the U.S. Food and Drug Administration for potential approval.
Days after reaching a tentative agreement with a majority of states involved in litigation against the company over its role in the opioid crisis in the United States, Purdue Pharmaceuticals filed Chapter 11 bankruptcy.
SpringWorks Therapeutics, Inc. announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $18.00 per share.
Baxter International Inc., a leading global medical products company, has entered into a definitive agreement to acquire Cheetah Medical, an Israel-based leading provider of non-invasive hemodynamic monitoring technologies with offices in Boston, Massachusetts as well as Tel Aviv, as detailed in the company press release.
Biocrates Life Sciences AG, one of the world’s leading biotech companies in the field of metabolomics, is strategically realigning.
Shares of 10X Genomics surged more than 35% on its first day of trading to close at $52.75, well above its $39 initial price offering starting point.
Silence Therapeutics, PLC announces its unaudited interim results for the half year to 30 June 2019.
The startup’s unique technology allows to halt the development of the short memory impairment that is characteristic of the patients with various neurodegenerative diseases.
Funds will enable company to finalize regulatory process with view to obtaining CE mark for ultra-fast robotized ophthalmology laser
G Protein Coupled Receptor (GPCR) expert will invest up to €3M ($3.3M) to unlock the therapeutic potential of breakthrough asset